Search research articles
Contact Us
Filters
Showing results (61-70 of 73) with videos related to
Page
of 8
Sort By:
Journal of Diabetes Science and Technology
|
August 16, 2021
Acute and Chronic Glucose Control in Critically Ill Patients With Diabetes: The Impact of Prior Insulin Treatment
James S Krinsley, Peter Rule, Michael Brownlee, et al.
American Journal of Speech-Language Pathology
|
October 19, 2023
Evaluating the Efficacy of a Narrative Language Intervention for Bilingual Students
Philip Capin, Sharon Vaughn, Sandra Laing Gillam, et al.
JAMA Cardiology
|
July 21, 2016
Time Course of Subsequent Shocks After Initial Implantable Cardioverter-Defibrillator Discharge and Implications for Driving Restrictions
Faisal M Merchant, Michael H Hoskins, Michael E Benser, et al.
Targeted Oncology
|
March 6, 2014
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial
Brian I Rini, David I Quinn, Michael Baum, et al.
JAMA Cardiology
|
May 16, 2019
Association of Ambulatory Hemodynamic Monitoring of Heart Failure With Clinical Outcomes in a Concurrent Matched Cohort Analysis
Jacob Abraham, Rupinder Bharmi, Orvar Jonsson, et al.
The Journal of Biological Chemistry
|
March 31, 2007
Cellular characterization of a novel focal adhesion kinase inhibitor
Jill K Slack-Davis, Karen H Martin, Robert W Tilghman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2012
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors
Jeffrey R Infante, D Ross Camidge, Linda R Mileshkin, et al.
Investigational New Drugs
|
September 4, 2015
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors
Suzanne F Jones, Lillian L Siu, Johanna C Bendell, et al.
Cancer Research
|
November 13, 2003
Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy
Jean S Beebe, Jitesh P Jani, Elisabeth Knauth, et al.
Cancer Research
|
March 15, 2008
Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271
Walter Gregory Roberts, Ethan Ung, Pamela Whalen, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 73) with videos related to
Sort By:
Page
of 8
Journal of Diabetes Science and Technology
|
August 16, 2021
Acute and Chronic Glucose Control in Critically Ill Patients With Diabetes: The Impact of Prior Insulin Treatment
James S Krinsley, Peter Rule, Michael Brownlee, et al.
American Journal of Speech-Language Pathology
|
October 19, 2023
Evaluating the Efficacy of a Narrative Language Intervention for Bilingual Students
Philip Capin, Sharon Vaughn, Sandra Laing Gillam, et al.
JAMA Cardiology
|
July 21, 2016
Time Course of Subsequent Shocks After Initial Implantable Cardioverter-Defibrillator Discharge and Implications for Driving Restrictions
Faisal M Merchant, Michael H Hoskins, Michael E Benser, et al.
Targeted Oncology
|
March 6, 2014
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial
Brian I Rini, David I Quinn, Michael Baum, et al.
JAMA Cardiology
|
May 16, 2019
Association of Ambulatory Hemodynamic Monitoring of Heart Failure With Clinical Outcomes in a Concurrent Matched Cohort Analysis
Jacob Abraham, Rupinder Bharmi, Orvar Jonsson, et al.
The Journal of Biological Chemistry
|
March 31, 2007
Cellular characterization of a novel focal adhesion kinase inhibitor
Jill K Slack-Davis, Karen H Martin, Robert W Tilghman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2012
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors
Jeffrey R Infante, D Ross Camidge, Linda R Mileshkin, et al.
Investigational New Drugs
|
September 4, 2015
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors
Suzanne F Jones, Lillian L Siu, Johanna C Bendell, et al.
Cancer Research
|
November 13, 2003
Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy
Jean S Beebe, Jitesh P Jani, Elisabeth Knauth, et al.
Cancer Research
|
March 15, 2008
Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271
Walter Gregory Roberts, Ethan Ung, Pamela Whalen, et al.
Page
of 8